Engineered RGD‐Treg‐Exos Targeted Delivery of miR‐218‐5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease
Advanced Science · 2025
DOI: 10.1002/advs.202412034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Zhaochen Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210016, …. Hauptthemen laut MEDLINE: MicroRNAs, Podocytes, Mitophagy, Diabetic Nephropathies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Project of Jiangsu Commission of Health, Key Research and Development Program of Jiangsu Province, Medical Innovation Center of Kidney Disease.
Abstract (Originalsprache)
Diabetic kidney disease (DKD) is the main cause of end‐stage kidney disease, and podocyte injury is an important factor in the development of DKD. Mitophagy is severely inhibited in the podocytes of patients. Damaged mitochondria aggregate in the cytoplasm and can not be removed effectively. Restoring mitophagy may be a novel strategy for the treatment of DKD. In this study, Regulatory T cells (Tregs) are found to reduce podocyte injury in DKD through exosomes. Sequencing and cross‐sectional analysis revealed that exosomes from Tregs delivered miR‐218‐5p to increase mitophagy in podocytes by inhibiting the TNC/TLR4/SRC/FUNDC1 pathway. Treg‐Exos are engineered to express RGD peptides on the membrane surface. RGD‐Treg‐Exos bind to integrins on the surface of podocytes and effectively target podocytes for the delivery of miR‐218‐5p, thus increasing mitophagy in podocytes, reducing cell apoptosis, and alleviating podocyte injury. In summary, this study revealed that engineered RGD‐Treg‐Exos effectively ameliorated podocyte injury in DKD, thus constituting a novel method for DKD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210016, China.
- Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210016, China.
- State Key Laboratory of Pharmaceutical Biotechnology, Medical School, Nanjing University, Nanjing, 210093, China.
ORCID-Profile: Hao Bao
Förderung
- Medical Research Project of Jiangsu Commission of Health
- Key Research and Development Program of Jiangsu Province
- Medical Innovation Center of Kidney Disease
Zitieren
APA
Guo, Z., Gao, S., Wang, Z., Chen, Z., Chen, J., Duan, A., Xu, F., Wang, Q., Qin, W., Zeng, C., Liu, Z., & Bao, H. (2025). Engineered RGD‐Treg‐Exos Targeted Delivery of miR‐218‐5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease. Advanced Science. https://doi.org/10.1002/advs.202412034
Vancouver
Guo Z, Gao S, Wang Z, Chen Z, Chen J, Duan A, et al. Engineered RGD‐Treg‐Exos Targeted Delivery of miR‐218‐5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease. Advanced Science. 2025. doi:10.1002/advs.202412034
BibTeX
@article{Guo2025,
author = {Guo, Zhaochen and Gao, Shaohui and Wang, Ziyue and Chen, Zige and Chen, Jinglei and Duan, Aiping and Xu, Feng and Wang, Qinger and Qin, Weisong and Zeng, Caihong and Liu, Zhihong and Bao, Hao},
title = {Engineered RGD‐Treg‐Exos Targeted Delivery of miR‐218‐5p to Activate Mitophagy and Attenuate Podocyte Injury in Diabetic Kidney Disease},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202412034}
}
EUVIMED